VCEL Stock Price, Chart, Stats & News

Vericel Corp Ord
Save
Vericel Corp Ord (VCEL) does not currently pay a dividend.
2.43B
Market cap
113.07x
Current P/E
99.01x
Forward P/E
VCEL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 74.42% |
Operating margin | 4.00% |
Pretax margin | 6.29% |
Net margin | 5.98% |
Effective tax rate | 4.94% |
ROA | 3.39% |
ROE | 5.17% |
D/E | 0.28x |
Interest coverage ratio | 17.53x |
VCEL valuation
P/E | 113.07x |
P/S | 5.39x |
P/B | 4.19x |
P/CF | 28.59x |
P/FCF | 42.47x |
P/OCF | 28.59x |
PEG | 3.89x |
EV multiple | 50.16x |
About
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children.
Similar securities
Based on sector and market capitalization
Report issue











